# Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

> **NCT03310580** · PHASE2 · COMPLETED · sponsor: **Aerie Pharmaceuticals** · enrollment: 42 (actual)

## Conditions studied

- Primary Open Angle Glaucoma or Ocular Hypertension

## Interventions

- **DRUG:** AR-13324 Ophthalmic Solution 0.02%
- **DRUG:** AR-13324 Ophthalmic Solution 0.04%
- **DRUG:** AR-13324 Ophthalmic Solution Placebo

## Key facts

- **NCT ID:** NCT03310580
- **Lead sponsor:** Aerie Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-15
- **Primary completion:** 2018-10-25
- **Final completion:** 2018-10-25
- **Target enrollment:** 42 (ACTUAL)
- **Last updated:** 2019-12-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03310580

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03310580, "Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03310580. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*